OR WAIT null SECS
Latest in Lipids and Trials to Watch in 2025, with Viet Le, DMSc, PA-C
Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.
The cardiology field has been rapidly expanding over the past few years, with breakthroughs that would take decades in any other specialty cropping up just days apart from one another.
This immense progress was highlighted this year at the American College of Cardiology (ACC) 2025 Annual Scientific Sessions for over 4,750 abstracts, with 1,300 expert faculty and 300 sessions, covering 53 different late-breaking clinical trials.
A leading expert in the field, Viet Le, DMSc, PA-C, a preventive cardiology PA at Intermountain Health and the former president of the Academy of Physician Associates in Cardiology, spoke with the editorial team of HCPLive about upcoming studies and anticipated breakthroughs for the rest of 2025.
HCPLive: What are you looking forward to in cardiology for the rest of 2025?
Le: As a researcher, I look forward to all the ongoing trials in this space. Lipoprotein(a) [Lp(a)] is starting to take front and center stage as we get into these final moments of follow-up for at least one of the four studies that are out there. I'm involved with the HORIZON study with pelacarsen, and I am so excited to see where that reports out. I'm hoping that we'll see some type of result, maybe the end of this year, or maybe the first quarter of 2026. I look forward to that, and we have a couple of trials coming from Intermountain [Health]. There's the Target-D trial, where we're looking at vitamin D levels in an acute coronary syndrome (ACS) population. And then, of course, we have our CorCal trial, where we're looking at coronary artery calcium scoring versus the Pooled Cohort Equation in terms of statin eligibility and uptake in statin use, as well as the lowering of LDL-C. We're all asking, is this the appropriate thing to do? Stay tuned, those are things I'm excited about. Of course, there are SGLT inhibitors and GLP-1 trials that are coming, so it's an exciting time for cardiovascular medicine.
Relevant disclosures for Le include Novartis, Pfizer, Amgen, and Janssen.
